1. Home
  2. MCHX vs XLO Comparison

MCHX vs XLO Comparison

Compare MCHX & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

SELL

Current Price

$1.29

Market Cap

60.3M

ML Signal

SELL

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$7.31

Market Cap

56.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCHX
XLO
Founded
2003
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.3M
56.9M
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
MCHX
XLO
Price
$1.29
$7.31
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $18.00
AVG Volume (30 Days)
★ 27.8K
11.1K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $90,291,000.00
$43,766,000.00
Revenue This Year
$17.69
N/A
Revenue Next Year
$29.82
$22.76
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 589.88
52 Week Low
$1.15
$0.46
52 Week High
$2.00
$25.17

Technical Indicators

Market Signals
Indicator
MCHX
XLO
Relative Strength Index (RSI) 43.60 21.78
Support Level $1.20 $0.46
Resistance Level $1.46 $8.97
Average True Range (ATR) 0.09 0.51
MACD 0.01 -0.16
Stochastic Oscillator 30.00 8.86

Price Performance

Historical Comparison
MCHX
XLO

About MCHX Marchex Inc. Class B

Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: